Brokerages expect United Therapeutics Co. (NASDAQ:UTHR) to post earnings per share of $2.84 for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for United Therapeutics’ earnings, with estimates ranging from $2.63 to $2.96. United Therapeutics reported earnings of $2.41 per share during the same quarter last year, which indicates a positive year over year growth rate of 17.8%. The company is scheduled to issue its next earnings results on Wednesday, August 4th.
On average, analysts expect that United Therapeutics will report full year earnings of $10.11 per share for the current financial year, with EPS estimates ranging from $9.43 to $11.04. For the next year, analysts forecast that the business will post earnings of $14.50 per share, with EPS estimates ranging from $11.86 to $15.99. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for United Therapeutics.
United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 5th. The biotechnology company reported $0.61 EPS for the quarter, missing analysts’ consensus estimates of $2.60 by ($1.99). The business had revenue of $379.10 million for the quarter, compared to analysts’ expectations of $368.31 million. United Therapeutics had a net margin of 26.92% and a return on equity of 12.27%. The company’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same period last year, the business posted $3.61 EPS.
A number of analysts recently commented on the stock. Credit Suisse Group lifted their target price on shares of United Therapeutics from $169.00 to $196.00 and gave the stock an “outperform” rating in a research note on Monday, March 1st. Oppenheimer lifted their target price on shares of United Therapeutics from $200.00 to $275.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 16th. HC Wainwright lifted their target price on shares of United Therapeutics from $195.00 to $248.00 and gave the stock a “buy” rating in a research note on Wednesday, May 12th. Wedbush lifted their price objective on shares of United Therapeutics from $255.00 to $260.00 and gave the company an “outperform” rating in a research note on Thursday, February 25th. They noted that the move was a valuation call. Finally, JPMorgan Chase & Co. lifted their price objective on shares of United Therapeutics from $185.00 to $212.00 and gave the company an “overweight” rating in a research note on Wednesday, April 14th. Seven analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus target price of $227.14.
In related news, Director Judy D. Olian sold 2,103 shares of the business’s stock in a transaction on Wednesday, March 17th. The shares were sold at an average price of $170.00, for a total value of $357,510.00. Following the completion of the transaction, the director now directly owns 7,893 shares in the company, valued at approximately $1,341,810. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Judy D. Olian sold 4,207 shares of the business’s stock in a transaction on Thursday, April 1st. The shares were sold at an average price of $184.96, for a total transaction of $778,126.72. Following the completion of the transaction, the director now owns 9,997 shares of the company’s stock, valued at $1,849,045.12. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,410 shares of company stock valued at $1,154,689. Company insiders own 12.00% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of UTHR. Amundi Pioneer Asset Management Inc. increased its holdings in United Therapeutics by 18.8% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 76,221 shares of the biotechnology company’s stock worth $8,945,000 after acquiring an additional 12,087 shares in the last quarter. IBM Retirement Fund purchased a new stake in United Therapeutics in the 4th quarter worth $245,000. Nisa Investment Advisors LLC increased its holdings in United Therapeutics by 10.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 22,071 shares of the biotechnology company’s stock worth $3,350,000 after acquiring an additional 2,106 shares in the last quarter. Clark Capital Management Group Inc. purchased a new stake in United Therapeutics in the 4th quarter worth $3,558,000. Finally, JJJ Advisors Inc. grew its holdings in shares of United Therapeutics by 775.0% during the fourth quarter. JJJ Advisors Inc. now owns 245 shares of the biotechnology company’s stock worth $37,000 after buying an additional 217 shares in the last quarter. 95.01% of the stock is owned by institutional investors.
Shares of United Therapeutics stock traded up $1.00 on Friday, reaching $186.74. The stock had a trading volume of 1,963 shares, compared to its average volume of 365,341. The company has a 50 day moving average price of $198.75 and a 200 day moving average price of $168.49. The stock has a market capitalization of $8.37 billion, a P/E ratio of 20.63 and a beta of 0.51. The company has a quick ratio of 6.36, a current ratio of 6.66 and a debt-to-equity ratio of 0.23. United Therapeutics has a 1 year low of $98.37 and a 1 year high of $212.62.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Further Reading: How is a management fee different from a performance fee?
Get a free copy of the Zacks research report on United Therapeutics (UTHR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com